PMC:7108637 / 72850-73956 JSONTXT

{"project":"2_test","denotations":[{"id":"29579213-22114560-45167963","span":{"begin":172,"end":176},"obj":"22114560"},{"id":"29579213-23133379-45167964","span":{"begin":192,"end":196},"obj":"23133379"},{"id":"29579213-22114560-45167965","span":{"begin":265,"end":269},"obj":"22114560"},{"id":"29579213-20844579-45167966","span":{"begin":484,"end":488},"obj":"20844579"},{"id":"29579213-24074577-45167967","span":{"begin":504,"end":508},"obj":"24074577"},{"id":"29579213-17151111-45167968","span":{"begin":690,"end":694},"obj":"17151111"},{"id":"29579213-22491453-45167969","span":{"begin":1078,"end":1082},"obj":"22491453"},{"id":"29579213-23292036-45167970","span":{"begin":1100,"end":1104},"obj":"23292036"},{"id":"T1401","span":{"begin":172,"end":176},"obj":"22114560"},{"id":"T52984","span":{"begin":192,"end":196},"obj":"23133379"},{"id":"T40764","span":{"begin":265,"end":269},"obj":"22114560"},{"id":"T12157","span":{"begin":484,"end":488},"obj":"20844579"},{"id":"T71471","span":{"begin":504,"end":508},"obj":"24074577"},{"id":"T27347","span":{"begin":690,"end":694},"obj":"17151111"},{"id":"T81702","span":{"begin":1078,"end":1082},"obj":"22491453"},{"id":"T55999","span":{"begin":1100,"end":1104},"obj":"23292036"}],"text":"Dense O-glycosylation of viral proteins has been widely described to provide “bulk” shielding from host immunity, and protect from antibody neutralization (Machiels et al. 2011; Kropff et al. 2012). Besides shielding select immunodominant epitopes (Machiels et al. 2011), highly O-glycosylated mucin-like domains, such as those found in Ebola and Marburg viruses, have been suggested to physically hinder the interaction between virus-infected cells and immune cells (Francica et al. 2010; Noyori et al. 2013). Conversely, the deletion of the Ebola virus mucin-like domain decreased the immune response in mice, although it did not have an effect on immunogenicity in vitro (Dowling et al. 2007). Finally, O-glycans not only shield, but in some cases can be presented as part of neo-epitopes when elongation of the glycans is prevented. As an example, several O-glycosylated immunodominant B-cell epitopes have been reported for HSV-2 and EBV, by probing O-glycopeptides with sera of infected patients, suggesting that the glycan moiety can be recognized by B-cells (Clo et al. 2012; D’Arrigo et al. 2013)."}